Coratus Genetics has closed on $5 million of a $25 million credit facility it secured from Boston Scientific one year ago.

Corautus (AMEX: CAQ) can get another $2.5 million when the first patient is enrolled in a Phase IIb clinical trial for a treatment of severe cardiovascular disease.

Boston Scientific has invested $17.5 million in Coratus to date.
Corautus is focused on gene transfer therapy products.